1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Eisai Co., Ltd.

Eisai Co., Ltd.

ESAIY
Eisai Co., Ltd.US flagOther OTC
5.80
USD
-0.11
- -
6.55BMarket Cap
Eisai Co., Ltd.
ESAIY
(Other OTC)

Recent

price

5.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2,818.93
2,698.58
2,273.69
2,012.85
2,100.74
1,919.29
1,917.39
1,885.08
2,096.95
2,243.7
2,427.01
2,253.68
659.46
648.98
646.58
696.03
321.18
Revenue per Share
141.58
236.52
205.33
169.38
134.04
151.36
192.24
137.63
181.18
221.24
424.84
146.34
41.82
48.33
36.97
40.94
16.82
Basic EPS, GAAP
269.17
351.3
249.63
187.2
223.89
201.55
194.37
195.29
436.53
265.59
183.37
124.59
67.25
-31.67
27.17
6.3
12.07
Free Cash Flow per Basic Share
140
150
150
149.99
149.9
149.81
150
150.03
150.02
149.93
159.97
160.03
40.01
40.01
40.02
40.16
20.03
Dividend per Share
1,645.23
1,731.59
1,786.74
1,805.88
1,486.47
1,515.07
1,539.59
1,538.45
1,607.35
1,687.49
1,920.15
1,923.79
480.99
494.98
498.15
491.03
498.15
Book Value per Share
336.43
498.92
648.45
835.97
923.97
1,017.19
1,042.08
1,105.41
1,194.1
1,332.19
1,492.78
1,563.62
422.35
457.29
503.07
491.35
474.1
Tangible Book Value per Share
285
285
285
285
285
286
286
286
286
287
287
287
1,147
1,147
1,147
1,134
1,146
Basic Weighted Avg Shares
803,138
768,925
647,925
573,676
599,490
548,465
547,922
539,097
600,054
642,834
695,621
645,942
756,226
744,402
741,751
789,400
368,199
Sales/Revenue/Turnover
10.76
14.71
14.78
12.28
11.08
5.17
9.48
10.96
12.87
13.4
18.04
7.97
7.11
5.38
7.2
6.89
5.97
Operating Margin (%)
57,370
51,264
48,694
51,093
39,929
38,940
34,064
26,484
26,183
26,841
33,700
35,767
38,398
39,981
39,398
39,906
19,874
Depreciation Expense
40,338
67,394
58,511
48,275
38,251
43,253
54,934
39,359
51,845
63,386
121,767
41,942
47,954
55,432
42,407
46,433
19,278
Net Income, GAAP
44.99
33.92
37.73
32.03
38.2
- -
- -
26.74
29.14
25.68
4.37
19.1
16.05
- -
29.18
21.3
25.04
Effective Tax Rate (%)
5.02
8.76
9.03
8.42
6.38
7.89
10.03
7.3
8.64
9.86
17.5
6.49
6.34
7.45
5.72
5.88
5.24
Profit Margin (%)
259,800
284,243
317,903
314,987
258,440
265,659
293,089
260,464
294,235
265,942
269,440
262,327
327,273
323,257
418,511
355,365
355,068
Working Capital
385,811
339,882
299,308
237,618
195,740
205,846
203,593
163,474
156,738
89,905
54,945
49,908
94,893
84,904
134,773
99,832
99,814
LT Debt
421,740
410,370
423,427
474,303
529,404
602,062
576,829
602,591
614,098
651,982
702,630
726,360
771,533
822,571
898,975
865,968
844,323
Total Equity
5.51
9.05
7.48
6.08
5.21
- -
- -
5.38
6.76
8.03
15.03
5.16
5.33
- -
3.75
4.03
1.6
Return on Invested Capital (%)
4.95
8.16
7.18
6.21
5.53
- -
- -
5.89
7.75
9.45
18.68
6.41
7.73
- -
5.81
6.25
2.64
Return on Capital (%)
8.61
14.01
11.67
9.43
8.15
10.09
12.59
8.95
11.52
13.44
23.56
7.61
8.7
9.9
7.44
8.23
3.37
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
24,632
- -
83,085
LT Borrowings
134,773
- -
99,814
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
287
- -
282
Market Capitalization
1,789,377
1,899,392
1,522,583

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
722,983
- -
681,907
Cash, Cash Equivalents & STI
305,123
- -
269,146
Accounts Receivable, Net
217,208
- -
195,221
Inventories
174,651
- -
192,091
Total Current Liabilities
304,472
- -
326,839
Payables & Accruals
- -
- -
- -
ST Debt
24,632
- -
83,085
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.8%
4.37%
-3.67%
Free Cash Flow
-27.54%
-65.21%
-77.07%
Net Income, GAAP
9.51%
-9.93%
9.49%
Sales/Revenue/Turnover
3.94%
2.89%
6.42%
Total Cash Common Dividend
0.64%
-0.13%
-0.81%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
196,935
176,617
177,703
190,496
741,751
2025
- -
- -
- -
- -
789,400
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
17.74
2.43
5.2
- -
36.97
2025
- -
- -
- -
- -
40.94
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
20.01
- -
20.01
- -
40.02
2025
- -
- -
- -
- -
40.16
2026
- -
- -
- -
- -
- -
Similar Companies
Global Hemp Group Inc. (GHG.CN)
N4 Pharma Plc (N4P.L)
Orchid Pharma Limited (ORCHPHARMA.NS)
Mountain Valley MD Holdings Inc. (MVMD.CN)
Kamada Ltd. (KMDA)
Aytu BioPharma, Inc. (AYTU)
Business
Eisai Co., Ltd. (ESAIY) develops, manufactures and markets prescription pharmaceuticals with a primary focus on neurology and oncology therapeutics. The company offers anti-epileptic drugs including Fycompa (perampanel) for partial onset and primary generalized tonic-clonic seizures; Alzheimer's disease treatments led by Leqembi (lecanemab) in partnership with Biogen; migraine therapies such as Aubagio (teriflunomide); and oncology products including Lenvima (lenvatinib) for various cancers; alongside supportive care solutions for neglected tropical diseases like lymphatic filariasis. Eisai operates an integrated model encompassing research, development, manufacturing and global marketing, serving patients and healthcare providers across neurology, oncology and other unmet medical needs areas. Founded in 1941 and headquartered in Tokyo, Japan, the company maintains R&D sites in Japan, the United States, United Kingdom and Singapore; production facilities in Japan, China, India, Indonesia, United States and United Kingdom; and sales subsidiaries in over 40 countries spanning the Americas, Europe, Asia, Africa and Oceania. Recent developments include the March 2025 tender offer to acquire EcoNaviSta Inc., following a July 2024 business alliance, to integrate its "Life Rhythm Navi" elderly monitoring SaaS into Eisai's dementia platform for enhanced prevention and early detection capabilities; a December 2024 memorandum of understanding with Fujirebio for diagnostic collaborations; a February 2025 licensing agreement with SciClone Pharmaceuticals subsidiary for drug commercialization; ongoing commitment of JPY 625 million to the GHIT Fund through FY2027 for infectious disease medicines in developing countries; and a 2024 share buyback of up to 6.5 million shares for JPY 30 billion to optimize capital structure.

Company News

APIChat

  • seekingalpha.com

    Eisai Co., Ltd. (ESAIY) Analyst/Investor Day Transcript

  • seekingalpha.com

    Eisai Co., Ltd. (ESAIY) Q4 2026 Earnings Call Transcript

  • reuters.com

    Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage study

  • marketwatch.com

    These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.

  • prnewswire.com

    Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer's Disease at the 78th American Academy of Neurology's Annual Meeting

  • prnewswire.com

    Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

  • seekingalpha.com

    Eisai Co., Ltd. (ESAIY) Q3 2026 Earnings Call Transcript

  • seekingalpha.com

    Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiatives, ESG, and Dementia Area Contributions Transcript

  • prnewswire.com

    Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025

  • prnewswire.com

    Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025

  • seekingalpha.com

    Eisai Co., Ltd. (ESAIY) Q2 2026 Earnings Call Transcript

  • reuters.com

    Merck, Eisai discontinue late-stage study for liver cancer therapy

  • reuters.com

    Merck-Eisai's cancer drug combo meets one main goal in late-stage study

  • prnewswire.com

    Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease

  • seekingalpha.com

    Eisai Co., Ltd. (ESAIY) Discusses On Latest Data On Lemborexant And Novel Orexin Receptor Agonist E2086 At The World Sleep 2025 Transcript

  • prnewswire.com

    Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025

  • prnewswire.com

    Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

  • reuters.com

    US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug

  • seekingalpha.com

    Eisai Co., Ltd. (ESALF) Q1 2026 Earnings Call Transcript

  • reuters.com

    Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds